Why a Radioligand No-Show Costs Differently Than a Missed Fraction.

Why AI Efficiency Disappears Between the Demo and the Staffing Model.

Vendor AI demos show real efficiency that never reaches the staffing model. The workflow redesign and oversight cost behind AI value in radiation oncology. medsolvedynamics.com [http://medsolvedynamics.com] | team@medsolvedynamics.com [team@medsolvedynamics.com] #AIinHealthcare #RadiationOncology #WorkflowFit #OncologyOperations

Why a Radioligand No-Show Costs Differently Than a Missed Fraction.

Lutetium-177 has a half-life of about 6.6 days, so a radioligand therapy no-show is a paid dose decaying in your department. The dose economics behind theranostics scheduling and isotope supply. medsolvedynamics.com [http://medsolvedynamics.com] | team@medsolvedynamics.com [team@medsolvedynamics.com] #Theranostics #RadioligandTherapy #IsotopeSupply #OncologyOperations

Why AI Is Not a One-Time Purchase in Radiation Oncology

AI purchasing differs fundamentally from traditional capital and software decisions. The cost is not the license, it is the recurring monitoring as the model drifts in ways no tolerance table catches. From hype to value: how to evaluate AI for long-term cost structure, clinical accountability, and organizational readiness, not the demo. medsolvedynamics.com [http://medsolvedynamics.com] | team@medsolvedynamics.com [team@medsolvedynamics.com]  #RadiationOncology #AIinHealthcare #OncologyLeadership #HealthcareAI

Why a Theranostics No-Show Hurts Differently Than an IMRT One

In radiation oncology, a curative no-show is a slot you backfill. In theranostics, the Lu-177 dose is a fixed amount with about a five-day shelf life, scheduled for one patient, and it cannot wait for a better day. Here is how scheduling discipline, authorized user coverage, and capture mechanics determine whether a theranostics service line holds its margin, and the two operating costs the vendor proforma leaves out. medsolvedynamics.com [http://medsolvedynamics.com] | team@medsolvedynamics.com [team@medsolvedynamics.com]  #Theranostics #RadiationOncology #RadiopharmaceuticalTherapy #OncologyOperations

A Guideline Says It Is Appropriate. The Next Question Is Whether Your Program Can Deliver It.

A society guideline on low-dose radiation for osteoarthritis makes benign disease a real service-line conversation in radiation oncology. Clinical appropriateness and program readiness are different questions. Here is the operational and financial read: the referral pathway, the payer coverage and prior-authorization pathway, and using open LINAC capacity for incremental benign volume without affecting the curative schedule. medsolvedynamics.com [http://medsolvedynamics.com] | team@medsolvedynamics.com [team@medsolvedynamics.com]  #RadiationOncology #Osteoarthritis #ServiceLineGrowth #BenignDisease